NVTA - Invitae Corporation

NYSE - NYSE Delayed Price. Currency in USD
8.55
+0.22 (+2.64%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close8.33
Open8.30
Bid0.00 x 0
Ask0.00 x 0
Day's Range8.27 - 8.58
52 Week Range7.03 - 11.88
Volume380,108
Avg. Volume322,887
Market Cap452.682M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.53
Earnings DateFeb 12, 2018 - Feb 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.67
Trade prices are not sourced from all markets
  • Capital Cube6 days ago

    ETFs with exposure to Invitae Corp. : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Invitae Corp. Here are 5 ETFs with the largest exposure to NVTA-US. Comparing the performance and risk of Invitae Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their Families
    PR Newswire12 days ago

    Multigene Genetic Testing Improves Identification and Management of Hereditary Cancer Risk for Breast Cancer Patients and Their Families

    -- Invitae to present findings at 2017 San Antonio Breast Cancer Symposium -- SAN ANTONIO , Dec. 5, 2017 /PRNewswire/ -- Research presented today by Invitae Corporation (NYSE: NVTA), one of the fastest ...

  • 3 Great Stocks Under $10
    Motley Fool13 days ago

    3 Great Stocks Under $10

    Petrobras, Invitae, and SunPower have a lot to offer long-term investors.

  • Capital Cube16 days ago

    ETFs with exposure to Invitae Corp. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Invitae Corp. Here are 5 ETFs with the largest exposure to NVTA-US. Comparing the performance and risk of Invitae Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Invitae Corp. :NVTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
    Capital Cube17 days ago

    Invitae Corp. :NVTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017

    Categories: Yahoo FinanceGet free summary analysis Invitae Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Invitae Corp. – Radius Health Inc, Fibrocell Science, Inc., Celldex Therapeutics, Inc. and HTG Molecular Diagnostics, Inc. (RDUS-US, FCSC-US, CLDX-US and HTGM-US) that have also reported for this period. ... Read more (Read more...)

  • Thomson Reuters StreetEvents17 days ago

    Edited Transcript of NVTA earnings conference call or presentation 6-Nov-17 9:30pm GMT

    Q3 2017 Invitae Corp Earnings Call

  • Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services
    PR Newswirelast month

    Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services

    SAN FRANCISCO, Nov. 15, 2017 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetic information companies, today announced it has completed its acquisition of CombiMatrix, which specializes in providing genetic information for prenatal diagnosis, miscarriage analysis and diagnosis of pediatric developmental disorders, establishing Invitae as a new leader in family and reproductive genetic health services. "With the addition of CombiMatrix to Invitae, we have completed our entry into prenatal and perinatal genetics, currently the second-largest category of genetic testing services.

  • Will Invitae Ever Turn a Profit?
    Motley Foollast month

    Will Invitae Ever Turn a Profit?

    The genetic-testing leader is growing at a triple-digit clip, but losses continue to mount.

  • GlobeNewswirelast month

    CombiMatrix Corporation Stockholders Approve Merger Agreement With Invitae Corporation

    IRVINE, Calif., Nov. 10, 2017-- CombiMatrix Corporation, a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announced today that, ...

  • Invitae Corporation Issues Reminder Regarding Exchange Offer for CombiMatrix Corporation Series F Warrants
    PR Newswirelast month

    Invitae Corporation Issues Reminder Regarding Exchange Offer for CombiMatrix Corporation Series F Warrants

    SAN FRANCISCO, Nov. 8, 2017 /PRNewswire/ -- Invitae Corporation (NVTA) one of the fastest growing genetic information companies, today issued a reminder to CombiMatrix Corporation Series F warrant holders regarding the previously announced offer to exchange (the "Exchange Offer") each outstanding Series F warrant (CUSIP No. 20009T147) (the "CombiMatrix Series F warrants") to acquire one share of common stock of CombiMatrix Corporation ("CombiMatrix") for 0.3056 of a share of common stock, par value $0.0001 per share, of Invitae (the "Invitae Common Stock").  All of the previously disclosed terms and conditions of the Exchange Offer remain unchanged.

  • Associated Presslast month

    Invitae reports 3Q loss

    The San Francisco-based company said it had a loss of 57 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017
    PR Newswirelast month

    Invitae Reports Double-Digit Sequential Volume and Revenue Growth in Third Quarter 2017

    Momentum in base business complemented by strategic expansion into family health genetics Hosting conference call today at 4:30 pm ET / 1:30 pm PT SAN FRANCISCO , Nov. 6, 2017 /PRNewswire/ --  Invitae ...

  • Invitae Presents Validation of a Novel NGS-based Preimplantation Genetic Screening Technology to Identify the Most Frequent Chromosomal Causes of Miscarriage
    PR Newswire2 months ago

    Invitae Presents Validation of a Novel NGS-based Preimplantation Genetic Screening Technology to Identify the Most Frequent Chromosomal Causes of Miscarriage

    SAN ANTONIO, Oct. 30, 2017 /PRNewswire/ -- Invitae (NVTA), one of the fastest growing genetic information companies, is presenting validation data for a novel, NGS-based preimplantation genetic screening (PGS) technology that accurately identifies certain chromosomal abnormalities potentially missed on other PGS platforms. In addition, company researchers are sharing data suggesting that if initial PGS testing yields no results, a second biopsy may provide actionable information.

  • Capital Cube2 months ago

    Invitae Corp. – Value Analysis (NYSE:NVTA) : October 26, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Invitae Corp. a score of 56. Our analysis is based on comparing Invitae Corp. with the following peers – Radius Health Inc, Fibrocell Science, Inc., Celldex Therapeutics, Inc. and HTG Molecular Diagnostics, Inc. (RDUS-US, FCSC-US, CLDX-US and HTGM-US). Investment Outlook Invitae Corp. has a fundamental score of ... Read more (Read more...)

  • Invitae Corp. breached its 50 day moving average in a Bearish Manner : NVTA-US : October 25, 2017
    Capital Cube2 months ago

    Invitae Corp. breached its 50 day moving average in a Bearish Manner : NVTA-US : October 25, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Invitae Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Invitae to announce third quarter 2017 Financial Results and Host Conference Call on November 6, 2017
    PR Newswire2 months ago

    Invitae to announce third quarter 2017 Financial Results and Host Conference Call on November 6, 2017

    SAN FRANCISCO, Oct. 24, 2017 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetic information companies, today announced that it will report its third quarter 2017 financial results on Monday, November 6, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments. The dial-in numbers for the conference call are (844) 579-6824 for domestic callers and (763) 488-9145 for international callers, and the reservation number for both is 99386744. Invitae Corporation (NVTA) is one of the fastest growing genetic information companies in the United States.

  • Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection
    PR Newswire2 months ago

    Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection

    Presentation at the American Society of Human Genetics Annual Meeting also highlights use of virtual panels to identify clinically important secondary findings SAN FRANCISCO , Oct. 17, 2017 /PRNewswire/ ...

  • 3 Signs Myriad Genetics' High-Growth Days Are Over
    Motley Fool2 months ago

    3 Signs Myriad Genetics' High-Growth Days Are Over

    The genetic testing leader may never return to its former glory.

  • Invitae Commences Exchange Offer for CombiMatrix Series F Warrants
    PR Newswire2 months ago

    Invitae Commences Exchange Offer for CombiMatrix Series F Warrants

    SAN FRANCISCO, Oct. 6, 2017 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetic information companies, today announced that it has commenced an offer to exchange (the "Exchange Offer") each outstanding Series F warrant (CUSIP No. 20009T147) (the "CombiMatrix Series F Warrants") to acquire one share of common stock of CombiMatrix Corporation ("CombiMatrix") for 0.3056 of a share of common stock, par value $0.0001 per share, of Invitae (the "Invitae Common Stock"). The Exchange Offer will expire at 12:00 midnight, New York City time, on November 13, 2017 (one minute after 11:59 p.m., New York City time, on November 12, 2017), or any other date and time to which Invitae extends the Exchange Offer (such date and time, as it may be extended, the "Expiration Date").

  • Invitae's new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wide
    PR Newswire2 months ago

    Invitae's new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wide

    SAN FRANCISCO, Oct. 5, 2017 /PRNewswire/ -- As genetic testing grows both more complex and more integrated into mainstream medical care, continually improving how genetic variants are classified as pathogenic, benign or unknown is essential. Researchers with Invitae Corporation (NVTA), one of the fastest growing genetic information companies, have developed and validated a new framework that refines genetic variant classification guidelines, resulting in a more complete and consistent approach that can be reproduced across genetic testing laboratories. Featured in the October print issue of Genetics in Medicine, the variant classification framework could increase consistency in classification industry-wide.

  • 3 Top Small-Cap Stocks to Buy in October
    Motley Fool2 months ago

    3 Top Small-Cap Stocks to Buy in October

    These smaller companies hold big potential.

  • Invitae Corp. breached its 50 day moving average in a Bullish Manner : NVTA-US : October 3, 2017
    Capital Cube2 months ago

    Invitae Corp. breached its 50 day moving average in a Bullish Manner : NVTA-US : October 3, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Invitae Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • PR Newswire2 months ago

    Atlas Genetics Appoints Life Sciences Veteran, Jeffrey Luber, as Chief Executive Officer; Founding CEO Dr John Clarkson Steps Up to Executive Chairman

    Atlas Genetics Ltd., the ultra-rapid, point-of-care (POC) testing company for women's and family health, today announced that Jeffrey R. Luber has been appointed Chief Executive Officer effective 1 October 2017. Dr John Clarkson, current founding CEO, will become Executive Chairman and current chairman, Neil Butler, will remain with the Company as a non-executive director of the Board. Mr. Luber joins the Board of Atlas Genetics with broad experience in the life sciences industry, including having held multiple leadership roles in both public and private companies.

  • Capital Cube3 months ago

    ETFs with exposure to Invitae Corp. : September 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Invitae Corp. Here are 5 ETFs with the largest exposure to NVTA-US. Comparing the performance and risk of Invitae Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Invitae Corp. : September 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Invitae Corp. Here are 5 ETFs with the largest exposure to NVTA-US. Comparing the performance and risk of Invitae Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)